WCN25-2015 EFFICACY OF RITUXIMAB IN MINIMAL CHANGE DISEASE AND FOCAL SEGMENTAL GLOMERULOSCLEROSIS : A SINGLE CENTRE EXPERIENCE FROM INDIA

Rituximab has emerged as a promising therapeutic option for patients with frequently relapsing or steroid-dependent nephrotic syndrome (FR/SDNS). Both Minimal Change disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) pose significant clinical challenges due to their potential for frequent relapses and dependency on corticosteroids, leading to substantial morbidity and a diminished quality of life. Rituximab has shown to reduce relapse and corticosteroid dependency.